Journal of Andrology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yeh, K. H.
Right arrow Articles by Yasuda, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yeh, K. H.
Right arrow Articles by Yasuda, N.

Journal of Andrology, Vol 15, Issue 3 187-193, Copyright © 1994 by The American Society of Andrology

JOURNAL ARTICLE

Participation of vasoactive intestinal polypeptide (VIP) as a humoral mediator in the erectile response of canine corpus cavernosum penis

K. H. Yeh, H. Aoki, J. Matsuzaka, S. Ra, F. Sato, T. Fujioka, T. Ohhori, T. Kubo and N. Yasuda
Department of Urology, School of Medicine, Iwate Medical University, Japan.

The ability of anti-vasoactive intestinal peptide (anti-VIP) serum to suppress the electrically induced relaxation of the corpus cavernosum was evaluated in vitro to define the role of VIP in penile erection. Strips of canine corpora cavernosa were placed in 5-ml organ chambers containing oxygenated Krebs-Ringer solution. They were stretched and fixed in place at both ends and pretreated with 2 x 10(-7)M noradrenaline (NA). NA was given to produce an optimal state of isometric smooth muscle contraction so that subsequent electrical field stimulation (EFS) could induce a good range of measurable relaxation response. This response was deemed to be an in vitro representation of penile erection. After NA treatment the cavernous tension rose markedly by 2-2.5 g; it then declined by up to 1-1.2 g upon EFS. Anti-VIP serum (1:16) or atropine sulfate (10(-6)M) was added at various time points between NA administration and EFS. When anti-VIP serum was administered, subsequent EFS-induced relaxation was attenuated by 20%-55% compared to the control EFS treatments. The degree of attenuation depended upon the frequency of EFS applied, being 20.6% +/- 4.0% at 20 Hz and 54.7% +/- 6.3% at 2 Hz. Atropine administered additionally following anti-VIP serum produced no further attenuation. However, atropine alone was capable of producing up to 23.7% +/- 3.5% attenuation. When anti-VIP serum was administered following atropine, the degree of attenuation that ensured was the sum of the attenuations produced by each of the two substances independently.(ABSTRACT TRUNCATED AT 250 WORDS)




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by The American Society of Andrology.